<DOC>
	<DOCNO>NCT00884442</DOCNO>
	<brief_summary>The present study perform investigate compare in-vivo performance two investigational product Gen-nifedipine extend release , ( previously refer Gen-Nifedipine XL ( Genpharm ULC , Canada ) ) Nifedipine ( Bayer Healthcare AG manufacture Adalat® XL® , Adalat® LA , Adalat® Crono , Adalat® OROS ) compare pharmacokinetic parameter oral single dose administration fast fed state .</brief_summary>
	<brief_title>Nifedipine Bioavailability Study With Oral Single Doses Under Fasting Fed Conditions</brief_title>
	<detailed_description>In past , several attempt make develop nifedipine formulation pharmacokinetic characteristic similar unique characteristic nifedipine GITS . A new extended release nifedipine tablet base osmotically active system day administration register trade name Gen-nifedipine extend release , ( previously refer Gen-Nifedipine XL ( Genpharm ULC , Canada ) ) Canada . According product monograph Gen-nifedipine extend release , ( previously refer Gen-Nifedipine XL ) , tablet consist semipermeable membrane surround osmotically active drug core . After contact water GI tract osmotic pressure core increase , release active drug control rate orifice tablet membrane . The functional principle nifedipine tablet seem quite similar one GITS system . However , especially case modify release formulation , various factor affect absorption systemic availability drug . Two important factor ) drug release rate dosage form ii ) gastrointestinal transit rate , turn influence site absorption . Especially food intake caloric content meal affect drug transit time , luminal dissolution drug permeability . Thus , prandial state may significant impact vivo behaviour formulation whole particularly drug bioavailability . For GITS formulation , Adalat® XL® , Adalat® LA , Adalat® Crono , Adalat® OROS , early study demonstrate significant influence concomitant food-intake occurs .</detailed_description>
	<mesh_term>Nifedipine</mesh_term>
	<criteria>1. sex : male 2. ethnic origin : Caucasian 3. age : 18 55 year , inclusive 4. bodymass index ( BMI ) : ³ 22 kg/m² £ 27 kg/m² 5. good state health ( clinically significant deviation normal clinical result laboratory finding ) 6. subject must give write informed consent , inform benefit potential risk trial , well detail insurance take cover subject 's participating study 1. exist cardiac haematological disease and/or pathological finding , might interfere drug 's safety , tolerability , absorption and/or pharmacokinetics 2. exist hepatic and/or renal disease and/or pathological finding , might interfere drug 's safety , tolerability , absorption and/or pharmacokinetics 3. exist gastrointestinal disease and/or pathological finding , include severe gastrointestinal esophageal constriction narrowing , might interfere drug 's safety , tolerability , absorption and/or pharmacokinetics 4. history relevant CNS and/or psychiatric disorder and/or currently treat CNS and/or psychiatric disorder 5. relevant pathological change ECG ( 12 standard lead ) second thirddegree AV block , complete bundle branch block , prolongation QRS complex 120 msec QTcinterval 450 msec 6. know allergic intolerance reaction active ingredient use constituent pharmaceutical preparation ( e.g . lactose intolerance ) 7. subject severe allergy multiple drug allergy 8. systolic blood pressure 110 mmHg 155 mmHg 9. diastolic blood pressure 60 mmHg 95 mmHg 10. rest heart rate awake subject 45 bpm 90 bpm 11. laboratory value normal range unless deviation normal judge relevant study investigator 12. positive antiHIVtest , HBsAGtest antiHCVtest Lack suitability trial 13. acute chronic disease could affect absorption metabolism 14. history current drug alcohol dependence 15. regular intake alcoholic food beverage ≥ 40 g pure ethanol per day 16. subject diet could affect pharmacokinetics drug 17. regular intake caffeine contain food beverage ≥ 500 mg ( calculated caffeine ) per day 18. heavy smoker ( ≥ 10 cigarette per day equivalent nicotine contain product ) 19. blood donation blood loss 400 ml within last two month prior start study 20. participation clinical trial last two month prior individual enrolment subject 21. regular treatment systemically available medication ( except hormonal replacement therapy e.g . Lthyroxine ) 22. subject , report frequent occurrence migraine attack Administrative reason 23. subject suspect know follow instruction 24. subject unable understand write verbal instruction , particular regard risk inconvenience expose result participation study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Bioavailability</keyword>
	<keyword>Nifedipine</keyword>
</DOC>